phrykt

Protara Therapeutics, Inc. (TARA): who owns it and who trades it

As of Nov 16, 2026, TARA insiders reported 3 open-market sales worth $1M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jesse Shefferman (CEO), with $882K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Protara Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns TARA

120 funds and institutions reported TARA shares worth $177M at the end of Q2 2026, about 86% of the company. The largest holder is Jupiter Topco LLC with 8.7%.

Funds and institutions (13F) 86%Everyone else 14%

10 largest owners, by share of the company

Jupiter Topco LLC8.7%
BlackRock, Inc.6.8%
Millennium Management LLC5.7%
Velan Capital Investment Management LP5.3%
Vanguard Capital Management LLC4.3%
Blackstone Inc.4.2%
Orbimed Advisors LLC4.1%
Sio Capital Management, LLC3.6%
Acorn Capital Advisors, LLC3.2%
Integral Health Asset Management, LLC2.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Jupiter Topco LLC4.70M8.68%$17.9M–
BlackRock, Inc.3.66M6.77%$14M+8%
Millennium Management LLC3.10M5.73%$11.8M+10%
Velan Capital Investment Management LP2.84M5.26%$10.9M+0%
Vanguard Capital Management LLC2.30M4.25%$8.8M+9%
Blackstone Inc.2.27M4.19%$8.7MNo change
Orbimed Advisors LLC2.22M4.10%$8.5M–
Sio Capital Management, LLC1.92M3.55%$7.3M-2%
Acorn Capital Advisors, LLC1.75M3.24%$6.7MNo change
Integral Health Asset Management, LLC1.50M2.77%$5.7M-14%
5AM Venture Management, LLC1.37M2.53%$5.2MNo change
Geode Capital Management, LLC1.33M2.45%$5.1M+13%
Citadel Advisors LLC1.23M2.28%$4.7M+15%
State Street Corp1.07M1.98%$4.1M+6%
Qube Research & Technologies Ltd1.05M1.93%$4M+491%
Balyasny Asset Management L.P.1.03M1.90%$3.9M–
Baker Bros. Advisors LP971,6141.80%$3.7MNo change
ADAR1 Capital Management, LLC940,5121.74%$3.6MNo change
Bank of America Corp882,1791.63%$3.4M-5%
Marshall Wace, LLP701,0211.30%$2.7M+1282%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, TARA insiders reported $0 of open-market purchases and $1M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$1M
3 trades, 2 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jun 29, 2026
Filed Jul 1, 2026

Purchases and sales by month

$882K$882KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 29, 2026Jesse SheffermanCEOSale215,687$4.09$882KForm 4
Apr 8, 2026Jacqueline ZummoChief R&D OfficerSale1,134$5.40$6.1KForm 4
Apr 1, 2026Jacqueline ZummoChief R&D OfficerSale22,598$5.26$119KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jesse SheffermanCEO and President, Director–$882KJun 29, 2026
Jacqueline ZummoChief R&D Officer–$125KApr 8, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TARA short interest

Moderate short interest. 5.5% of TARA shares are sold short: about 1 share in 18. Over the last 12 reports the number of shares short went down 13%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.24M TARA shares were sold short, 5.5% of the shares outstanding, down 46.9% from the report before. At the average daily volume of 1.13M shares, buying them all back would take about 2.9 trading days (days to cover).

Shares short, % of all shares

5.48%May 15Oct 3011.7%

Days to cover

2.9May 15Oct 3013.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.24M5.48%-47%1.13M2.9
Oct 15, 20266.09M10.31%+5%1.41M4.3
Sep 30, 20265.79M9.80%+31%1.99M2.9
Sep 15, 20264.42M7.47%-0%427,22910.3
Aug 31, 20264.43M7.50%-2%358,56912.4
Aug 14, 20264.54M7.68%+1%377,53412.0
Jul 31, 20264.50M8.31%-1%392,04411.5
Jul 15, 20264.54M8.40%+5%676,2626.7
Jun 30, 20264.34M8.02%-3%847,3635.1
Jun 15, 20264.47M8.26%-24%682,1896.5
May 29, 20265.89M10.89%+57%953,7376.2
May 15, 20263.74M6.91%-38%665,9615.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Protara Therapeutics company events

Protara Therapeutics filed 12 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 6, 2026.

  1. Nov 6, 2026ResultsReleased financial results. Filing
  2. Aug 11, 2026ResultsReleased financial results. Filing
  3. Jun 29, 2026LeadershipProtara Therapeutics, Inc. announced that Leonardo Viana Nicacio, M.D., Chief Medical Officer of the Company, resigned from the Company to explore other opportunities, effective as of June 26, 2026. Filing
  4. Jun 15, 2026VoteReported shareholder vote results. Filing
  5. May 13, 2026ResultsReleased financial results. Filing
  6. Mar 30, 2026AnnouncementShared information with investors. Filing
  7. Mar 10, 2026ResultsReleased financial results. Filing
  8. Feb 24, 2026AnnouncementThe Company will present updated interim data from its ongoing Phase 2 open-label ADVANCED-2 Trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1) NMIBC at poster sessions at the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancer Symposium in San Francisco… Filing
  9. Dec 15, 2025AnnouncementAs previously disclosed, on December 8, 2025, Protara Therapeutics, Inc. completed a public offering of an aggregate of 13,043,479 shares of common stock of the Company, par value $0.001 per share. Filing
  10. Dec 8, 2025AgreementProtara Therapeutics, Inc. entered into an Underwriting Agreement with J.P. Morgan Securities LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters named therein, pursuant to which the Company agreed to sell and issue to the Underwriters an aggregate… Filing
  11. Dec 3, 2025AnnouncementThe Company presented updated interim data from its ongoing Phase 2 open-label ADVANCED-2 Trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1) NMIBC at a poster session at the 2025 Annual Meeting of the Society of Urologic Oncology (SUO) Conference, reporting positive results that… Filing
  12. Nov 19, 2025AnnouncementThe Company announced interim results from its ongoing Phase 2 STARBORN-1 clinical trial of TARA-002 in pediatric patients with Lymphatic Malformations during a conference call. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Protara Therapeutics financials

Famous investors that hold TARA

5 of the 50 well-known investors we track reported holding TARA in their latest 13F filing. The largest position is Israel Englander's, worth $9.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20263.10M$9.4M0.0%-0%
Ken Griffin · Citadel AdvisorsQ3 20262.09M$6.4M0.0%+69%
Jim Simons · Renaissance TechnologiesQ3 2026531,830$1.6M0.0%+111%
Steve Cohen · Point72 Asset ManagementQ3 2026205,272$626K0.0%-63%
Ken Fisher · Fisher Asset ManagementQ3 2026129,612$395K0.0%+30%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named TARA in the last 120 days.

FiledHolderFormStake
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A0.0%
Nov 16, 2026JANUS HENDERSON GROUP Ltd.13G/A0.0%

Questions about Protara Therapeutics, Inc. (TARA) stock

Who owns the most TARA stock?

The largest reported owner of Protara Therapeutics, Inc. (TARA) is Jupiter Topco LLC, with 8.7% of the company. In total, 120 funds and institutions reported holding TARA at the end of Q2 2026, together about 86% of the shares. See the largest owners.

Are TARA insiders buying or selling?

In the last 12 months, TARA insiders reported no open-market purchases and 3 sales worth $1M. The latest trade was on Jun 29, 2026. See every trade.

What is the short interest in TARA?

As of Oct 30, 2026, 3.24M TARA shares were sold short, 5.5% of the shares outstanding, down 46.9% from the report before. At the average daily volume of 1.13M shares, buying them all back would take about 2.9 trading days (days to cover). See the history.

Which famous investors hold TARA?

5 of the 50 well-known investors we track reported TARA in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $9.4M. See all holders.

Executive pay

Protara Therapeutics's chief executive was paid a total of $2.7M for the year ended Dec 31, 2025, up 48% from $1.8M the year before. In the last 12 months, Protara Therapeutics's executives and directors bought no stock on the open market and sold $1M.

Chief executive, total pay$2.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$2.3MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.4MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.